Kohjin Bio Co., Ltd. Stock

Equities

177A

JP3283630006

Pharmaceuticals

Market Closed - Japan Exchange 02:00:00 2024-06-14 am EDT 5-day change 1st Jan Change
1,724 JPY +0.41% Intraday chart for Kohjin Bio Co., Ltd. +2.13% 0.00%
Sales 2025 * 4.72B 29.96M Sales 2026 * 5.13B 32.58M Capitalization 8.65B 54.91M
Net income 2025 * 618M 3.92M Net income 2026 * 671M 4.26M EV / Sales 2025 * 1.83 x
Net cash position 2025 * - 0 Net cash position 2026 * - 0 EV / Sales 2026 * 1.69 x
P/E ratio 2025 *
13.8 x
P/E ratio 2026 *
12.9 x
Employees -
Yield 2025 *
0.81%
Yield 2026 *
0.81%
Free-Float 27.87%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.41%
1 week+2.13%
Current month-2.98%
1 month+5.57%
More quotes
1 week
1 651.00
Extreme 1651
1 760.00
1 month
1 466.00
Extreme 1466
1 922.00
Current year
1 466.00
Extreme 1466
2 375.00
1 year
1 466.00
Extreme 1466
2 375.00
3 years
1 466.00
Extreme 1466
2 375.00
5 years
1 466.00
Extreme 1466
2 375.00
10 years
1 466.00
Extreme 1466
2 375.00
More quotes
Date Price Change Volume
24-06-14 1,724 +0.41% 15,000
24-06-13 1,717 +0.76% 16,800
24-06-12 1,704 +1.43% 37,900
24-06-11 1,680 -1.35% 10,400
24-06-10 1,703 +0.89% 13,100

Delayed Quote Japan Exchange, June 14, 2024 at 02:00 am EDT

More quotes
Kohjin Bio Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of bacterial testing media, in vitro diagnostic drugs, cell culture media, as well as contract cell processing. The Company operates through three segments. The Tissue Culture business segment develops, manufactures, and sells tissue culture media, including serum-free media used for research purposes in regenerative medicine and immunotherapy. The Microbiology business segment develops, manufactures, and sells a wide variety of microorganism detection media used for pathogen testing in the clinical and food fields, and quality testing in various fields such as pharmaceuticals and cosmetics. The Cell Processing business segment conducts cell processing operations under contract from medical institutions at facilities that have obtained permission to manufacture specified cell products based on the Regenerative Medicine Safety Act.
More about the company

Annual profits - Rate of surprise